Business
Synchrony Financial: our business and in this report, we refer to as our "partners." The terms of the programs all require cooperative efforts between us and our partners of varying natures and degrees to establish and operate the programs.
Revenue decreased 2.8% to $18.99B, while Net income increased 1.5% to $3.55B.
The read at a glance✓ Audited against SEC data
- Earnings — FY2025 net income $3.55BOK
- Profitability — Net income $3.55BOK
- Balance-sheet lens — Credit, capital, funding and liquidityNote
- Accounting — Distress screen not applicable · manipulation and earnings-quality screens not computedNote
- Insiders — 0 buys; 23 sells in 365 daysNote
- Capital — dividends paid were $427.0M; share repurchases were $2.94BNote
Where the revenue comes from
Fiscal 2025, as Synchrony Financial reports it. History and quarterly detail are in the app.
- Synchrony$19.0B
Leadership changes
From Synchrony Financial's own filings, the day they're filed.
- Deborah Ellinger · director · appointmenteff. 2025-10-01
- Daniel Colao · director · appointmenteff. 2024-10-01
- Amy Tiliakos · President · appointmenteff. 2024-08-01
Latest filings
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-07-31
- 10-Q · Quarterly report2026-07-23
- 8-K · Company announcement2026-07-21
- 8-K · Company announcement2026-07-21
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Synchrony Financial, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.